Oral Agent for Diabetic Macular Edema Misses Mark but Still Shows Promise

Diabetes is a leading cause of vision loss, particularly due to conditions such as diabetic macular edema (DME). Recent research has explored innovative treatments, including an oral therapy known as tonabersat, designed to target this condition.

Trial Results

An investigational oral therapy for diabetic macular edema (DME) did not significantly affect retinal thickening in a placebo-controlled randomized trial.

After six months of treatment, the central subfield thickness (CST) showed a mean decrease of 15 µm with tonabersat, compared to a 5 µm increase in the placebo group. Despite an adjusted analysis yielding a 16 µm difference, this result did not achieve statistical significance (P=0.08).

When excluding patients who had received anti-VEGF therapy, a post-hoc analysis indicated a statistically significant adjusted mean difference of 21 µm (P=0.02). Notably, patients with higher baseline CST appeared to benefit more from tonabersat.

Comments from Researchers

Dr. Jennifer K. Sun from the National Eye Institute highlighted that while primary outcomes were not met, there were encouraging anatomical trends suggesting some efficacy. The studies noted difficulties in recruiting patients with thicker retinas, as those with good vision were less common in the study population.

Co-moderator Dr. Arshad Khanani pointed to the need for careful interpretation of dropout rates and the methodology used in the study. The utilization of last-observation-carried-forward (LOCF) might require closer evaluation to understand the study’s true efficacy.

Potential for Future Studies

Despite the mixed results, there is an interest in the possibility of conducting additional studies, specifically focusing on patients with thicker retinas who may derive more benefit from tonabersat. Other methodologies, such as fluorescein angiography, might also enhance patient selection in future trials.

According to Dr. Sun, while current treatments for DME are effective, there remains a significant portion of patients who do not experience benefits, leading to a demand for novel therapies that are less invasive and well-tolerated.

Conclusion

In summary, tonabersat’s oral therapy presents promise despite not meeting primary endpoints. Continued research is necessary to ascertain its place in the treatment landscape for diabetic macular edema. This ongoing exploration could yield new insights into effective treatments for individuals affected by this condition.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult a healthcare provider for personalized recommendations.

Fuente: https://www.medpagetoday.com/meetingcoverage/arvo/121186